Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

被引：15

作者：

Verstovsek, Srdan

Deeg, H. Joachim ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Zhu, Joy ^{[5
]}

Kantarjian, Hagop ^{[1
]}

Estrov, Zeev

Scott, Bart Lee ^{[2
]}

Thomas, Deborah A.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Fred Hutchinson Canc Res Ctr, Dept Clin Res, Seattle, WA 98104 USA

[3] Univ Washington, Seattle, WA 98195 USA

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] S BIO, Global Clin Dev, Redwood City, CA USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.3082.3082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1271 / 1271

页数：1

共 50 条

[1] SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
Hart, Stefan
Goh, Kee Chuan
Novotny-Diermayr, Veronica Veronica
Tan, Yong Cheng
Madan, Babita
Amalini, Chithra
Loh, Yung Kiang
Ong, Lai Chun
Williams, Anthony
Lee, Angeline
Poulsen, Anders
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Dymock, Brian W.
Wood, Jeanette M.
CANCER RESEARCH, 2011, 71
[2] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Hart, S.
Goh, K. C.
Novotny-Diermayr, V.
Tan, Y. C.
Madan, B.
Amalini, C.
Ong, L. C.
Kheng, B.
Cheong, A.
Zhou, J.
Chng, W. J.
Wood, J. M.
BLOOD CANCER JOURNAL, 2011, 1 : e44 - e44
[3] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
S Hart
K C Goh
V Novotny-Diermayr
Y C Tan
B Madan
C Amalini
L C Ong
B Kheng
A Cheong
J Zhou
W J Chng
J M Wood
Blood Cancer Journal, 2011, 1 : e44 - e44
[4] Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
Lee, Angeline
William, Anthony
Poulsen, Anders
Tan, Evelyn
Nagaraj, Harish
Goh, Kay Lin
Ong, Wai Chung
Goh, Kee Chuan
Pasha, Mohammed Khalid
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Wood, Jeanette M.
Dymock, Brian W.
CANCER RESEARCH, 2011, 71
[5] Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
Deeg, H. J.
Odenike, O.
Scott, B. L.
Estrov, Z.
Cortes, J. E.
Thomas, D. A.
Zhu, H. J.
Kantarjian, H.
Verstovsek, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA
Al-Fayoumi, S.
Wang, L.
Dean, J.
Benner, S.
HAEMATOLOGICA, 2013, 98 : 406 - 406
[7] FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS
Seymour, F.
To, B.
Goh, A.
Meadows, L.
Ethirajulu, A.
Wood, A.
Zhu, A.
Roberts, W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 472 - 472
[8] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S.
Seymour, John F.
Roberts, Andrew W.
Wadleigh, Martha
To, L. Bik
Scherber, Robyn
Turba, Elyce
Dorr, Andrew
Zhu, Joy
Wang, Lixia
Granston, Tanya
Campbell, Mary S.
Mesa, Ruben A.
BLOOD, 2015, 125 (17) : 2649 - 2655
[9] Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia Polycythemia Vera Myelofibrosis
Verstovsek, Srdan
Odenike, Olatoyosi
Scott, Bart
Estrov, Zeev
Cortes, Jorge
Thomas, Deborah A.
Wood, Jeanette
Ethirajulu, Kantharaj
Lowe, Ann
Zhu, Huan J.
Kantarjian, Hagop
Deeg, H. Joachim
BLOOD, 2009, 114 (22) : 1502 - 1502
[10] A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis
Padrnos, Leslie
Mesa, Ruben A.
EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (07): : 725 - 733

← 1 2 3 4 5 →